Edit
Replicate Bioscience
https://replicatebioscience.com/Last activity: 08.01.2026
Probably Closed
Location: United States
Total raised: $47M
Investors 1
| Date | Name | Website |
| - | Apple Tree... | appletreep... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.01.2026 | - | $7M | - |
| 08.09.2021 | Series A | $40M | Apple Tree... |
Mentions in press and media 13
| Date | Title | Description |
| 08.01.2026 | Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria | Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public health burdens, subject to humanitarian li... |
| 04.12.2025 | Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate’s Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America | Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate’s novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis Replicate to provide GMP material for clinical trials and transfer ... |
| 14.02.2024 | Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology | Replicate's srRNA vaccine elicited a protective immune response that met the WHO threshold for protection at unparalleled low doses Threshold for protection achieved with just a single dose of vaccine RBI-4000 well-tolerated at all doses te... |
| 10.07.2023 | Replicate Bioscience Appoints Rachael Lester as Chief Business Officer | Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team SAN DIEGO, Calif., July 10, 2023 – Replicate Bioscience, a company pioneering novel... |
| 10.07.2023 | Replicate Bioscience Appoints Rachael Lester as Chief Business Officer | Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team |
| 26.07.2022 | Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines | Companies aim to support development of up to 15 new genomic medicine products Replicate’s commercial licensing of lipid nanoparticle technology from Precision NanoSystems at foundation of deal SAN DIEGO, Calif., and Vancouver, British Co... |
| 26.07.2022 | Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines | Companies aim to support development of up to 15 new genomic medicine products |
| 08.09.2021 | ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience | NEW YORK and SAN DIEGO, Sept. 8, 2021 /PRNewswire/ -- ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat autoimmune a... |
| 08.09.2021 | ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience | NEW YORK and SAN DIEGO, Calif., September 8, 2021/PR NEWSWIRE/ – ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat a... |
| 08.09.2021 | ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience | NEW YORK and SAN DIEGO, Calif., September 8, 2021/PR NEWSWIRE/ – ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat a... |
Show more